一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Tertiary Lymphoid Structures in Brain Metastases of Lung Cancer: Prognostic Significance and Correlation With Clinical Outcomes.
Tertiary Lymphoid Structures in Brain Metastases of Lung Cancer: Prognostic Significance and Correlation With Clinical Outcomes.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们的研究结果揭示了肺癌来源的 BMs 中存在 TLSs,并强调了其独立于 GPA 指数的预后意义。在独特的中枢神经系统肿瘤微环境中鉴定出 TLS,为 BMs 的免疫景观提供了新的见解,并提示了针对这些结构进行免疫治疗干预以改善患者预后的潜在途径。
源自肺癌的脑转移(BMs)患者预后仍然较差,尽管治疗策略已取得进展。BMs肿瘤免疫微环境中三级淋巴结构(TLSs)的作用尚未得到广泛探索。
本研究利用17例经组织学确诊的肺癌脑转移患者来源的临床样本,这些患者接受了手术切除。采用免疫组化分析BM组织中TLS和TIL(肿瘤浸润淋巴细胞)(TILs)的存在及特征,并将其与临床结局进行关联。
在BM组织中鉴定出TLSs,尽管处于未成熟形式,将其与原发性肺癌组织中的成熟对应物区分开来。观察到TLS密度(而非TIL密度)与改善的术后生存之间存在显著相关性,突显了TLS密度作为独立预后标志物的潜力。此外,TLS密度与分级预后评估(GPA)指数不相关,表明其具有超越传统预测因子的独特预后价值。
This study utilized patient-derived clinical samples from 17 patients with histologically confirmed BMs of lung cancer, undergoing surgical resection. Immunohistochemistry was employed to analyze the presence and characteristics of TLS and tumor-infiltrating lymphocytes (TILs) within BM tissues, correlating these with clinical outcomes.
TLSs, albeit in their immature form, were identified within BM tissues, distinguishing them from their mature counterparts in primary lung cancer tissues. A significant correlation between TLS density (but not TIL density) and improved postoperative survival was observed, underscoring the potential of TLS density as an independent prognostic marker. Furthermore, TLS density did not correlate with the Graded Prognostic Assessment (GPA) index, suggesting its unique prognostic value beyond conventional predictors.
Our findings reveal the presence of TLSs in lung cancer-derived BMs and highlight their prognostic significance, independent of the GPA index. The identification of TLS within the unique central nervous system tumor microenvironment offers new insights into the immune landscape of BMs and suggests potential avenues for immunotherapeutic interventions targeting these structures to improve patient outcomes.
MEMBER ACCOUNT
登录成功会直接打开下一页。